Heather Wilson Robles

Cancer is the most common cause of death in dogs over the age of 2 years in the US

Up to 50% of all dogs over the age of 10 will develop cancer in their lifetimes.

With approx­i­mate­ly 77 million pet dogs in the United States, there are an estimated 6 million pet dogs diagnosed with cancer each year.

Earlier detection can save lives

It can also improve the quality of life of the dog and its owner.

Yet, as of today, there are few single assay cancer blood tests on the veterinary market. Currently, dogs suspected of having cancer are required to undergo a variety of diagnostic tests that may be expensive, time consuming, and painful for the animal.

For any questions, please email AskNu.​QVet@​volition.​com.

NU Q Vet Logo RGB

We hope to change this with the intro­duc­tion of the Nu.Q® Vet Cancer Screening Test – now available from the Gas­troin­testi­nal Laboratory (GI Lab) at Texas A&M University.

The Nu.Q® Vet Cancer Screening Test is a simple, cost effective, easy to use ELISA based screening blood test which will help streamline the diagnostic process for older or at risk” dogs.

Introduce the Nu.Q® Vet Cancer Screening Test as part of the annual wellness check for older dogs and at risk breeds.

How does the Nu.Q® Vet Cancer Screening Test work?

DNA is compacted within a cell’s nucleus in the form of nucleosomes which are bead-like structures comprised of DNA coiling around a histone protein core.

When a patient (human or canine) has cancer, nucleosomes from those cancer cells are released into the blood and can be measured using antibodies that are specific to nucleosomes. By measuring and analyzing nucleosomes, our Nu.Q® Vet Cancer Screening Test can identify patients who may have a cancer. This must then be confirmed by follow up procedures — for example, a biopsy or scan.

Vet­eri­nar­i­ans can click here to order today from the GI Lab at Texas A&M University.

Clinical Evidence

Results of a study of over 300 dogs have been published in a peer reviewed journal. A variety of breeds, weights and cancer stages were represented in the dataset with samples collected from Texas A&M’s Veterinary Clinic and NIH’s DCTC Biobank.

Lymphoma

At the recommended cut-off, the Nu.Q® Vet Cancer Screening Test detected 77% of lymphoma at 97% specificity versus control including all stages of lymphoma.

Click here view graph Click to read clinical paper

Heman­giosar­co­ma

At the recommended cut-off, the Nu.Q® Vet Cancer Screening Test detected 82% of heman­giosar­co­ma at 97% specificity versus control including stages I through III of hemangiosarcoma.

Click to view graph Click to read clinical paper

New Data

Nu.Q® Vet Cancer Monitoring Test in development. Nu.Q® Vet may serve as a more sensitive measurement of both minimal residual disease and remission and could be a useful monitoring test for dogs with cancer.

Click here to read the poster

Coming Soon.

Broadening the Range of Cancers Detected

  • Peer reviewed publication due soon.
  • Although the Nu.Q® Vet Cancer Screening Test has been marketed as a screening test for lymphoma and heman­giosar­co­ma, this Test can be useful in detecting other forms of cancer as well1 (1 =data on file)
  • Test performs best for tumors that are more systemic (high­er­metasta­t­ic rate) or those that have a high cellular turnover rate1.
  • Volition is also working to incorporate additional histone mod­i­fi­ca­tions into the test that will help to better dif­fer­en­ti­ate between various cancer types.

Dif­fer­en­tial Diagnosis

  • We are currently developing additional assays to add to the Nu.Q® test to better dif­fer­en­ti­ate inflam­ma­to­ry and other conditions from cancer.
  • Studies are underway at five university hospitals to collect data comparing a variety of concomitant conditions including:
    • Inflam­ma­to­ry conditions
    • Immune mediated disease
    • Endocrinopathies

Point of care test

  • To aid the timely provision of diagnosis and treatment response we are in the process of developing a POC test.

If you would like to find out more, contact us at: AskNu.​QVet@​volition.​com.

How to submit a sample

  • Patients should be fasted (minimum four hours) for this test to be accurate.
  • Draw down 2 – 5 mL of blood from a peripheral vein.
  • Immediately fill EDTA tube(s) with blood.
  • Spin the sample in-house at 1600xg (the blood” spin) for 10 minutes within one-hour of sampling and transfer plasma into a fresh tube. 
  • Ship overnight on ice, Sunday to Thursday (note: GI Lab is closed Saturday/​Sunday).
  • Only collect samples, Sunday to Thursday.
  • Reduced FedEx shipping is available through the GI Lab website.

    Note: Elevated levels have also been observed in a variety of systemic infectious and inflam­ma­to­ry diseases and are not specific for a particular cancer type.

    Results should be interpreted in clinical context in combination with history, physical exam and other diagnostic methods.

How to interpret the results

Consider using the Nu.Q® Vet Cancer Screening Test for younger dogs (4 years and older) with an increased risk for developing cancer in their lifetimes.

Low

Result:
<57.4 ng/mL

Cancer Suspicion Level:
Low

Moderate

Result:
57.4-67.4 ng/mL

Cancer Suspicion Level:
Moderate

High

Result:
67.4-600 ng/mL

Cancer Suspicion Level:
High

High to Very High

Result:
>600 ng/mL

Cancer Suspicion Level:
High to Very High

Case Studies

Intel­lec­tu­al Property

Covers human and veterinary applications

Believed to be the only company working on ELISA measurement for epi­ge­net­i­cal­ly modified circulating nucleosomes.

As of September 302021:

30

Patent families

12

Patents granted in the U.S.

14

Patents granted in Europe

56

Additional patents granted worldwide

82

Patents pending